Preconception Non-criteria Antiphospholipid Antibodies and Risk of Subsequent Early Pregnancy Loss: a Retrospective Study

Overview

Journal Reprod Sci

Publisher Springer

Specialty Reproductive Medicine

Date 2023 Nov 6

PMID 37932551

Authors

Fangxiang Mu

Mei Wang

Xianghui Zeng

Ling Liu

Fang Wang

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the subsequent early pregnancy outcomes in women positive for non-criteria antiphospholipid antibodies (NC-aPLs) before pregnancy. A total of 273 patients who had experienced sporadic or recurrent pregnancy loss and had been screened for 13 NC-aPLs at preconception were recruited in this study from September 2019 to February 2022. Serum levels of NC-aPLs were measured by ELISA using specific kits. The primary outcome was early pregnancy loss, and the secondary outcomes were biochemical pregnancy, clinically confirmed pregnancy loss, and ongoing pregnancy. Among these subjects, 56 patients had one previous pregnancy loss, and 217 had recurrent pregnancy loss (RPL). The NC-aPLs (+) and NC-aPLs (-) groups had similar rates of early pregnancy loss (EPL) after adjustment, regardless of the number of positive NC-aPLs (aOR = 1.054, 95% CI 0.602-1.846). Other outcomes were comparable in both groups, including the rates of biochemical pregnancy (aOR = 1.344, 95% CI 0.427-4.236), clinically confirmed pregnancy loss (aOR = 0.744, 95% CI 0.236-2.344), and ongoing pregnancy (aOR = 0.949, 95% CI 0.542-1.660). Based on sensitivity analysis, the NC-aPLs (+) were not associated with adverse early pregnancy outcomes in women with RPL. Furthermore, the difference in gestational weeks of pregnancy loss between the two groups was also insignificant. This study found no evidence linking preconception NC-aPL positivity to early pregnancy outcomes but offers a reference for future research to clarify NC-aPLs' potential clinical impact.

Citing Articles

Non-Criteria Obstetric Antiphospholipid Syndrome: Myth or Reality?.

Beca S, Borrell M, Cervera R, Figueras F, Nadal A, Espinosa G J Clin Med. 2025; 14(4).

PMID: 40004829 PMC: 11856706. DOI: 10.3390/jcm14041299.

Pregnancy Outcomes in Non-Criteria Obstetric Antiphospholipid Syndrome: Analysis of a Cohort of 91 Patients.

Beca S, Banos N, Borrell M, Ruiz-Ortiz E, Perez-Isidro A, Cervera R J Clin Med. 2025; 13(24.

PMID: 39768785 PMC: 11728320. DOI: 10.3390/jcm13247862.

Factors affecting biochemical pregnancy loss (BPL) in preimplantation genetic testing for aneuploidy (PGT-A) cycles: machine learning-assisted identification.

Ortiz J, Lledo B, Morales R, Manez-Grau A, Cascales A, Rodriguez-Arnedo A Reprod Biol Endocrinol. 2024; 22(1):101.

PMID: 39118049 PMC: 11308629. DOI: 10.1186/s12958-024-01271-1.

References

Vaiarelli A, Cimadomo D, Patrizio P, Venturella R, Orlando G, Soscia D . Biochemical pregnancy loss after frozen embryo transfer seems independent of embryo developmental stage and chromosomal status. Reprod Biomed Online. 2018; 37(3):349-357. DOI: 10.1016/j.rbmo.2018.05.019. View

Franasiak J, Forman E, Hong K, Werner M, Upham K, Treff N . The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril. 2013; 101(3):656-663.e1. DOI: 10.1016/j.fertnstert.2013.11.004. View

Demetrio Pablo R, Munoz Cacho P, Lopez-Hoyos M, Calvo-Rio V, Riancho-Zarrabeitia L, Martinez-Taboada V . Risk Factors for the Development of the Disease in Antiphospholipid Antibodies Carriers: A Long-term Follow-up Study. Clin Rev Allergy Immunol. 2021; 62(2):354-362. PMC: 8994711. DOI: 10.1007/s12016-021-08862-5. View

Yamada M, Kawakami T, Takashima K, Nishioka Y, Nishibata Y, Masuda S . Establishment of a rat model of thrombosis induced by intravenous injection of anti-phosphatidylserine-prothrombin complex antibody. Rheumatology (Oxford). 2017; 56(6):1013-1018. PMC: 5445602. DOI: 10.1093/rheumatology/kew477. View

Byrne A, Arts P, Ha T, Kassahn K, Pais L, ODonnell-Luria A . Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death. Nat Med. 2023; 29(1):180-189. PMC: 10333122. DOI: 10.1038/s41591-022-02142-1. View

Egri N, Bentow C, Rubio L, Norman G, Lopez-Sanudo S, Mahler M . Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk. Front Immunol. 2021; 12:754469. PMC: 8592011. DOI: 10.3389/fimmu.2021.754469. View

Zigon P, Pirkmajer K, Tomsic M, Kveder T, Bozic B, Semrl S . Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes. J Immunol Res. 2015; 2015:975704. PMC: 4452858. DOI: 10.1155/2015/975704. View

Ramirez G, Mackie I, Nallamilli S, Pires T, Moll R, Pericleous C . Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. Rheumatology (Oxford). 2020; 60(3):1376-1386. DOI: 10.1093/rheumatology/keaa509. View

Yang Q, Shi M, Shen Y, Cao Y, Zuo S, Zuo C . COX-1-derived thromboxane A2 plays an essential role in early B-cell development via regulation of JAK/STAT5 signaling in mouse. Blood. 2014; 124(10):1610-21. PMC: 5942862. DOI: 10.1182/blood-2014-03-559658. View

10.

Xourgia E, Tektonidou M . An Update on Antiphospholipid Syndrome. Curr Rheumatol Rep. 2022; 23(12):84. DOI: 10.1007/s11926-021-01051-5. View

11.

Bender Atik R, Christiansen O, Elson J, Kolte A, Lewis S, Middeldorp S . ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open. 2023; 2023(1):hoad002. PMC: 9982362. DOI: 10.1093/hropen/hoad002. View

12.

Dawaliby R, Trubbia C, Delporte C, Noyon C, Ruysschaert J, Van Antwerpen P . Phosphatidylethanolamine Is a Key Regulator of Membrane Fluidity in Eukaryotic Cells. J Biol Chem. 2015; 291(7):3658-67. PMC: 4751403. DOI: 10.1074/jbc.M115.706523. View

13.

Staub H, Bertolaccini M, Khamashta M . Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev. 2012; 12(2):230-4. DOI: 10.1016/j.autrev.2012.07.008. View

14.

Vlagea A, Pascual-Salcedo D, Alvarez Doforno R, Lavilla P, Diez J, Padilla Merlano B . IgA anti-β2 glycoprotein I antibodies: Experience from a large center. Thromb Res. 2017; 162:38-43. DOI: 10.1016/j.thromres.2017.12.007. View

15.

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

16.

Tong M, Viall C, Chamley L . Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum Reprod Update. 2014; 21(1):97-118. DOI: 10.1093/humupd/dmu049. View

17.

Kutteh W . Antiphospholipid antibody syndrome and reproduction. Curr Opin Obstet Gynecol. 2014; 26(4):260-5. DOI: 10.1097/GCO.0000000000000086. View

18.

Mauracher L, Krall M, Roiss J, Hell L, Koder S, Hofbauer T . Neutrophil subpopulations and their activation potential in patients with antiphospholipid syndrome and healthy individuals. Rheumatology (Oxford). 2020; 60(4):1687-1699. PMC: 8024003. DOI: 10.1093/rheumatology/keaa532. View

19.

Becarevic M . The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome. J Thromb Thrombolysis. 2016; 42(4):552-7. DOI: 10.1007/s11239-016-1389-5. View

20.

Zhang S, Wu Z, Li J, Wen X, Li L, Zhang W . Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome. Clin Rheumatol. 2016; 36(2):407-412. DOI: 10.1007/s10067-016-3510-8. View